FreeFlow™ Applications
Support for Drug Discovery
Analysis of precious material is enabled through ultra-sensitivity. This extends to quantitative calibrated Single Cell Analysis, which includes human primary cells and organoids.
Quantitative Organoid Analysis
Organoid analysis has become a powerful tool in life sciences research and drug discovery because it enables the study of human biology in systems that closely mimic the structure, cellular diversity, and function of real organs.
Derived from stem cells or patient tissues, organoids capture key aspects of tissue architecture and genetic heterogeneity that are often absent in traditional two-dimensional cell cultures. This physiological relevance improves the predictive power of preclinical studies, allowing researchers to better model disease mechanisms, host–pathogen interactions, and developmental processes.
In drug discovery, organoid-based assays support more accurate assessment of efficacy, toxicity, and drug response variability, including patient-specific responses, thereby reducing late-stage failure rates.
Overall, organoid analysis bridges the gap between in vitro models and human physiology, accelerating translational research and enabling more precise and efficient development of new therapeutics.
Single Cell Analysis of Human Primary Material
Single-cell protein analysis is highly valuable in life sciences research and drug discovery because it reveals functional cellular states and signaling activities that are masked in bulk measurements.
By quantifying proteins and post-translational modifications at single-cell resolution, these approaches capture cell-to-cell heterogeneity, dynamic pathway activation, and rare but biologically important subpopulations that often drive disease progression or therapeutic resistance.
This functional insight complements genomic and transcriptomic data, enabling a more complete understanding of how genetic programs are executed in health and disease.
In drug discovery, single-cell protein analysis improves target validation and mechanism-of-action studies, allows precise monitoring of on-target and off-target effects, and supports biomarker discovery for patient stratification. Together, these capabilities enhance the predictive power of preclinical models and contribute to the development of more effective and precisely targeted therapies.
Point of Care and Distributed Diagnostics
Point-of-care (POC) diagnostics provide rapid, actionable clinical information at or near the site of patient care, enabling timely decision-making without reliance on centralized laboratory infrastructure. By delivering results within minutes to hours, POC tests improve patient outcomes through earlier diagnosis, faster initiation of appropriate treatment, and reduced loss to follow-up, particularly in acute, emergency, and resource-limited settings. They also enhance healthcare efficiency by streamlining clinical workflows, lowering system costs, and reducing unnecessary referrals or hospital admissions.
In addition, POC diagnostics support personalized medicine by enabling real-time monitoring of disease progression and treatment response, empowering clinicians to adapt care pathways based on immediate, patient-specific data.
Distributed diagnostics extend diagnostic capabilities across decentralized networks—such as clinics, pharmacies, community settings, homes, and mobile units—rather than concentrating testing in centralized laboratories. This model improves access, efficiency and equity by bringing diagnostic services closer to patients, especially in rural, underserved, or hard-to-reach populations. Distributed diagnostics increase system resilience and scalability, as demonstrated during public health emergencies, by reducing bottlenecks and enabling rapid population-level testing and surveillance.
Overall, distributed diagnostics support more flexible, efficient, accessible, and resilient healthcare delivery while accelerating early detection and disease management at scale.
Longevity and Health Preservation
Point-of-care testing is a critical enabler of longevity and health preservation.
It allows individuals and clinicians to monitor key physiological and molecular markers frequently, conveniently, and in real time enabling clinical responses to be put in place immediately.
By providing rapid insights into metabolic health, inflammation, cardiovascular risk, immune function, and nutrient status, point-of-care tests support early detection of dysfunction long before clinical disease develops.
This timeliness enables proactive, preventive interventions—such as lifestyle adjustments, nutritional optimization, or targeted therapies—rather than reactive treatment of advanced illness.
Point-of-care testing also facilitates longitudinal tracking of personal health trajectories, helping to individualize interventions and assess their effectiveness over time. By shifting healthcare toward continuous monitoring and prevention, point-of-care testing plays a central role in extending healthspan, not just lifespan.
Information Request
Ask us for our latest information.
Data Request
"*" indicates required fields